The chemistry
CJC-1295 Ipamorelin: DAC vs No-DAC Explained
Why the Drug Affinity Complex stretches CJC-1295 to days, why Mod GRF (1-29) lasts minutes, and what that changes for the pairing.
The short version
When people say "CJC-1295," they could mean one of two different molecules — and the difference is the most important practical fact about the CJC-1295 Ipamorelin pairing. The two versions are called "with DAC" and "no-DAC," and the only thing separating them is a small chemical handle called a Drug Affinity Complex (DAC).
The DAC handle grabs onto albumin, a protein floating in your blood, and hangs on. That single trick keeps the peptide working for days instead of minutes. The "no-DAC" version — usually called Mod GRF (1-29) — has no handle, so an enzyme in the blood chops it up in about half an hour. Same basic GHRH signal, wildly different duration. This page explains the chemistry behind that gap and why it matters when CJC-1295 is paired with ipamorelin, whose own pulse is short.
What the DAC actually is
CJC-1295 with DAC is a tetra-substituted analogue of human GRF(1-29) carrying a C-terminal N-epsilon-maleimidopropionamide-lysine — the Drug Affinity Complex. That maleimide group reacts with the Cys34 thiol (a sulfur-bearing site) on serum albumin, forming a covalent thioether bond in the bloodstream. In rats, this bioconjugate produced about a 4-fold increase in GH area-under-the-curve over 2 hours versus unmodified hGRF(1-29), with albumin-bound peptide detectable in plasma beyond 72 hours [5].
The payoff in humans is dramatic duration. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days; after multiple doses, IGF-1 stayed above baseline for up to 28 days [1]. The DAC effectively converts a peptide that would last minutes into one that supplies a multi-day GHRH background — a half-life on the order of 6 to 8 days.
Mod grf 1-29: the no-DAC form
Mod grf 1-29 is CJC-1295 without the DAC: the same modified 29-amino-acid GHRH fragment, but with no albumin-binding handle. Its modifications (the amino-acid substitutions that make CJC-1295 resistant to dipeptidyl peptidase-IV, or DPP-IV) extend it beyond native GHRH, but without DAC it is still short-acting — roughly minutes to about 30 minutes, because DPP-IV rapidly cleaves GHRH-type peptides at the N-terminus [8].
That short, sharp action is the entire point of Mod GRF (1-29): it delivers a brief pulsatile GHRH signal rather than a sustained background, which some research protocols prefer for mimicking the body's natural pulsatile rhythm. The trade-off is obvious — a short half-life means the GHRH signal is gone quickly, where the DAC version maintains it for days. Which form is meant by "CJC-1295" changes the pharmacology of the whole pairing.
Why the DAC distinction changes the pairing
Ipamorelin's pulse is short — it clears within hours, peaking near 40 minutes [2]. Pairing it with the no-DAC Mod GRF (1-29) lines up two short-acting signals into a single coordinated pulse, the configuration closest to the synergy studies that used acute GHRP-plus-GHRH co-administration [3][4]. Pairing it with the DAC version is structurally different: a sharp ipamorelin pulse layered on a continuous, multi-day GHRH background.
That second configuration is a distinct exposure profile from anything the synergy literature actually studied. The synergy work measured acute co-stimulation [3]; chronic continuous GHRH-pathway drive from the DAC form is not the same experiment. This is one reason the fixed CJC-1295 + ipamorelin blend's net GH exposure is uncharacterized — even the choice of CJC-1295 form changes what "the combination" means, and neither configuration has been tested as a fixed blend in a controlled human trial [1].
Pulsatility and the DAC form
A reasonable worry about a multi-day GHRH signal is that it might flatten GH into a constant drip and abolish the natural pulses — which the body uses for signaling. The data is reassuring on this point. During continuous CJC-1295 stimulation in healthy men, pulsatile GH secretion persisted: pulse frequency and amplitude were unchanged while basal trough GH rose about 7.5-fold, yielding a 46% rise in mean GH and a 45% rise in IGF-1 [9].
So the DAC form raises the GH floor without erasing the rhythm laid on top of it. That preserved pulsatility is a meaningful pharmacodynamic reassurance for the GHRH-analogue concept generally — but it was measured for CJC-1295 alone, not for the CJC-1295 + ipamorelin combination, and it does not resolve the broader question of long-term safety for either form. The full studied-dose and half-life record is on the CJC-1295 Ipamorelin references and dosage pages.